The Medical Services Advisory Committee has finally recommended a prognostic genetic profiling test for breast cancer recurrence but at a very low fee and it is attempting to compel the company and any competitor to agree to 'fix' the price to private pathology companies.
Committee is now recommending that companies engage in price-fixing
October 18, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
Call for safety net change with half a million Australians missing out on cheaper medicines
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News -
Industry pushes back on conspiracy theories, highlighting the Government's own comments
March 22, 2025 - - Latest News -
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News